Drug and alcohol dependence reports最新文献

{"title":"Nicotine flux and pharmacokinetics-based considerations for early assessment of nicotine delivery systems","authors":"Aditya R. Kolli ,&nbsp;Emilija Veljkovic ,&nbsp;Florian Calvino-Martin ,&nbsp;Marco Esposito ,&nbsp;Arkadiusz K. Kuczaj ,&nbsp;Ondrej Koumal ,&nbsp;Jed E. Rose ,&nbsp;Manuel C. Peitsch","doi":"10.1016/j.dadr.2024.100245","DOIUrl":"https://doi.org/10.1016/j.dadr.2024.100245","url":null,"abstract":"<div><p>In the past few years, technological advancements enabled the development of novel electronic nicotine delivery systems (ENDS). Several empirical measures such as “nicotine flux” are being proposed to evaluate the abuse liability potential of these products. We explored the applicability of nicotine flux for clinical nicotine pharmacokinetics (PK) and 52-week quit success from cigarettes for a wide range of existing nicotine delivery systems. We found that the differences in nicotine flux for various nicotine delivery systems are not related to changes in PK, as nicotine flux does not capture key physiological properties such as nicotine absorption rate. Further, the 52-week quit success and abuse liability potential of nicotine nasal sprays (high nicotine flux product), and nicotine inhalers (nicotine flux similar to ENDS) are low, suggesting that nicotine flux is a poor metric for the assessment of nicotine delivery systems. PK indices are more dependable for characterizing nicotine delivery systems, and a nicotine plasma <span><math><mfrac><mrow><msub><mrow><mi>C</mi></mrow><mrow><mi>max</mi></mrow></msub></mrow><mrow><msub><mrow><mi>T</mi></mrow><mrow><mi>max</mi></mrow></msub></mrow></mfrac></math></span> &gt; 1 could improve 52-week quit success from cigarettes. However, a single metric may be inadequate to fully assess the abuse liability potential of nicotine delivery systems and needs to be further studied. A combination of <em>in vitro</em> and <em>in silico</em> approaches could potentially address the factors influencing the inhaled aerosol dosimetry and resulting PK of nicotine to provide early insights for ENDS assessments. Further research is required to understand nicotine dosimetry and PK for <em>ad libitum</em> product use, and abuse liability indicators of nicotine delivery systems. This commentary is intended to (1) highlight the need to think beyond a single empirical metric such as nicotine flux, (2) suggest potential PK-based metrics, (3) suggest the use of <em>in vitro</em> and <em>in silico</em> tools to obtain early insights into inhaled aerosol dosimetry for ENDS, and (4) emphasize the importance of considering comprehensive clinical pharmacology outcomes to evaluate nicotine delivery systems.</p></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"11 ","pages":"Article 100245"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772724624000295/pdfft?md5=37909534c08a2ec13225650a1f63ad1f&pid=1-s2.0-S2772724624000295-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141243003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Policies, adaptations, and ongoing challenges to naloxone, buprenorphine and nonprescription syringe access across four-states: Findings from an environmental scan and key Informant interviews","authors":"Anthony S. Floyd ,&nbsp;Joseph Silcox ,&nbsp;Gail Strickler ,&nbsp;Thuong Nong ,&nbsp;Malcolm Blough ,&nbsp;Derek Bolivar ,&nbsp;Megan Rabin ,&nbsp;Jeffrey Bratberg ,&nbsp;Adriane N. Irwin ,&nbsp;Daniel M. Hartung ,&nbsp;Ryan N. Hansen ,&nbsp;Robert Bohler ,&nbsp;Traci C. Green","doi":"10.1016/j.dadr.2024.100243","DOIUrl":"https://doi.org/10.1016/j.dadr.2024.100243","url":null,"abstract":"<div><h3>Background</h3><p>As the US opioid-involved morbidity and mortality increase, uptake and implementation of evidence-based interventions remain key policy responses. Respond to Prevent was a multi-component, randomized trial implemented in four states and two large pharmacy chains with the aim of improving the pharmacy’s capacity to provide naloxone, dispense buprenorphine, and sell nonprescription syringes (NPS). We sought to provide context and assess how policies and organizational practices affect communities and pharmacies across the study states.</p></div><div><h3>Methods</h3><p>Using a multi-method approach we: 1) conducted an environmental scan of published literature and online materials spanning January 2015 to June 2021, 2) created timelines of key events pertaining to those policies and practices and 3) conducted semi-structured interviews with stakeholders (key informants) at the state and local levels (N=36) to provide further context for the policies and practices we discovered.</p></div><div><h3>Results</h3><p>Key informants discussed state policies, pharmacy policies and local practices that facilitated access to naloxone, buprenorphine and NPSs. Interviewees from all states spoke about the impact of naloxone standing orders, active partnerships with community-based harm reduction organizations, and some federal and state policies like Medicaid coverage for naloxone and buprenorphine, and buprenorphine telehealth permissions as key facilitators. They also discussed patient stigma, access in rural settings, and high cost of medications as barriers.</p></div><div><h3>Conclusion</h3><p>Findings underscore the important role harm reduction-related policies play in boosting and institutionalizing interventions in communities and pharmacies while also identifying structural barriers where more focused state and local attention is needed.</p></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"11 ","pages":"Article 100243"},"PeriodicalIF":0.0,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772724624000271/pdfft?md5=00ed1fb7fdfde86d68963499e61aeb15&pid=1-s2.0-S2772724624000271-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141243001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fentanyl, carfentanil and other fentanyl analogues in Canada’s illicit opioid supply: A cross-sectional study","authors":"Robert A. Kleinman","doi":"10.1016/j.dadr.2024.100240","DOIUrl":"10.1016/j.dadr.2024.100240","url":null,"abstract":"<div><h3>Background</h3><p>Despite the increase in fentanyl-involved overdose deaths in Canada, there have been no national-level studies evaluating the proportion of illicit opioids containing fentanyl or fentanyl analogues in Canada.</p></div><div><h3>Methods</h3><p>This cross-sectional exploratory study characterized trends in fentanyl, carfentanil and other fentanyl analogues within opioids seized by law enforcement agencies in Canada from 2012 to 2022 and submitted to the Health Canada Drug Analysis Service (DAS). Analyses were stratified by province/region. Mann-Kandell tests were used to test for trends.</p></div><div><h3>Results</h3><p>A total of 157,616 samples containing any opioid (“opioid-containing samples”) were submitted to the DAS from Canadian provinces between 2012 and 2022, of which 81,165 (51.5%) contained fentanyl or a fentanyl analogue. The percentage of opioid-containing samples that were positive for fentanyl or a fentanyl analogue increased from 3.0% (95% CI: 2.6–3.4%) in 2012–68.3% (67.7–68.9%) in 2022 (p &lt; 0.001 for trend). The percentage of opioid-containing samples that were positive for fentanyl or a fentanyl analogue increased between 2012 and 2022 in all regions. In 2022, the percentage of samples containing fentanyl or an analogue followed an east-to-west gradient: 15.8% (13.3–18.6%) of samples in Atlantic Canada and 84.7% (83.6–85.7%) in British Columbia. Carfentanil was present in 4.9% (4.6–5.2%) of opioid-containing samples in Canada in 2022 and 19.7% (18.3–21.2%) of opioid-containing samples in Alberta.</p></div><div><h3>Conclusions</h3><p>The illicit opioid supply in Canada increasingly contains toxic synthetic opioids. As of 2022, important regional differences existed in the illicit opioid supply in Canada.</p></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"12 ","pages":"Article 100240"},"PeriodicalIF":0.0,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772724624000246/pdfft?md5=0b0344a0ce5ba0a2913ab6886ccba2b0&pid=1-s2.0-S2772724624000246-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141137122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot findings on the real-world performance of xylazine test strips for drug residue testing and the importance of secondary testing methods","authors":"Erin Thompson ,&nbsp;Jessica Tardif ,&nbsp;Merci Ujeneza ,&nbsp;Adina Badea ,&nbsp;Traci C. Green ,&nbsp;Haley McKee ,&nbsp;Michelle McKenzie ,&nbsp;Ju Nyeong Park","doi":"10.1016/j.dadr.2024.100241","DOIUrl":"10.1016/j.dadr.2024.100241","url":null,"abstract":"<div><h3>Background</h3><p>Xylazine is a sedative found increasingly in the illicit fentanyl supply that can cause hypotension, bradycardia, necrosis and death. This pilot examined the real-world performance of BTNX xylazine test strips (XTS) in drug residue samples.</p></div><div><h3>Methods</h3><p>This study was nested within a drug checking service in Rhode Island. We tested unmeasured drug residue dissolved in 5<!--> <!-->mL of distilled water using XTS and Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-QTOF-MS). Analyses compared XTS and LC-QTOF-MS results to calculate XTS detection of xylazine in residue.</p></div><div><h3>Results</h3><p>Among 41 residue samples, xylazine was detected in 11% by the XTS and 44 % by the laboratory. The LC-QTOF-MS detected xylazine in 18 samples: 4 major, 9 minor, 5 trace by volume relative to the whole sample. The XTS disagreed with the LC-QTOF-MS by indicating a negative result in 77.8 % (N=14) of the samples but never indicated a positive when the LC-QTOF-MS reported xylazine’s absence. The XTS correctly detected xylazine 22 % of the time, however, this increased to 100 % of the time if xylazine was a major active component.</p></div><div><h3>Conclusions</h3><p>In this study, the BTNX XTS often disagreed with LC-QTOF-MS by indicating a negative result, likely due to the dilution levels used and sample composition. The XTS may not be accurate in detecting residual amounts of xylazine, especially if xylazine is not a dominant component of the tested sample. Given the novelty of BTNX’s XTS products, we recommend XTS only be used in conjunction with other advanced drug checking modalities for residue testing.</p></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"11 ","pages":"Article 100241"},"PeriodicalIF":0.0,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772724624000258/pdfft?md5=56767014de9dc64ba0787efb30f0538b&pid=1-s2.0-S2772724624000258-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141027016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Substance use stigma: A systematic review of measures and their psychometric properties","authors":"Angelica Spata ,&nbsp;Ishita Gupta ,&nbsp;M. Kati Lear ,&nbsp;Karsten Lunze ,&nbsp;Jason B. Luoma","doi":"10.1016/j.dadr.2024.100237","DOIUrl":"https://doi.org/10.1016/j.dadr.2024.100237","url":null,"abstract":"<div><h3>Background</h3><p>Instruments to measure substance use stigma are emerging, however little is known regarding their psychometric properties. While research has evolved to view substance use stigma as a context sensitive international phenomenon that is embedded within cultures, validated self-report measures are lacking and comprehensive reviews of the existing measures are extremely limited. In this systematic review of substance use stigma and shame measures, we aim to contextualize results from existing research, lay the groundwork for future measurement development research, and provide a thorough resource for research scientists currently designing studies to measure substance use stigma.</p></div><div><h3>Methods</h3><p>We searched three databases using Boolean search terms for psychometric evaluations of measures of substance use stigma and shame and evaluated the quality/psychometric properties using an adaptation of the COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN) systematic review guidelines.</p></div><div><h3>Results</h3><p>We identified 18 measures of substance use stigma. Overall, most measures had minimal psychometric assessments and none of the measures met all domains of the COSMIN measure quality criteria. However, most studies reported satisfactory factor analyses and internal consistency scores.</p></div><div><h3>Conclusions</h3><p>Most measures of substance use stigma and shame had psychometric assessment across a limited range of criteria and no measures of structural substance use stigma were found. The most reported psychometric properties were structural validity and convergent validity. We suggest future researchers investigate test-retest reliability and cross-cultural validity for existing substance use stigma measures, as well as develop and evaluate novel measures assessing structural stigma of substance use.</p></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"11 ","pages":"Article 100237"},"PeriodicalIF":0.0,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772724624000210/pdfft?md5=d8a85beda8215dbade4df4b6d23e10f4&pid=1-s2.0-S2772724624000210-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140914056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating changes in overdose death rates from increasing methamphetamine supply in Ohio: Evidence from crime lab data","authors":"Daniel Rosenblum ,&nbsp;Jeffrey Ondocsin ,&nbsp;Sarah G. Mars ,&nbsp;Dennis Cauchon ,&nbsp;Daniel Ciccarone","doi":"10.1016/j.dadr.2024.100238","DOIUrl":"https://doi.org/10.1016/j.dadr.2024.100238","url":null,"abstract":"<div><h3>Background</h3><p>We investigate the relationship between the supply of methamphetamine and overdose death risk in Ohio. Ohio and the overall US have experienced a marked increase in overdose deaths from methamphetamine combined with fentanyl over the last decade. The increasing use of methamphetamine may be increasing the risk of overdose death. However, if people are using it to substitute away from more dangerous synthetic opioids, it may reduce the overall risk of overdose death.</p></div><div><h3>Methods</h3><p>Ohio’s Bureau of Criminal Investigation’s crime lab data include a detailed list of the content of drug samples from law enforcement seizures, which are used as a proxy for drug supply. We use linear regressions to estimate the relationship between the proportion of methamphetamine in lab samples and unintentional drug overdose death rates from January 2015 through September 2021.</p></div><div><h3>Results</h3><p>Relatively more methamphetamine in crime lab data in a county-month has either no statistically significant relationship with overdose death rates (in small and medium population counties) or a negative and statistically significant relationship with overdose death rates (in large population counties). Past overdose death rates do not predict future increases in methamphetamine in crime lab data.</p></div><div><h3>Conclusions</h3><p>The results are consistent with a relatively higher supply of methamphetamine reducing the general risk of overdose death, possibly due to substitution away from more dangerous synthetic opioids. However, the supply of methamphetamine appears unrelated to the past illicit drug risk environment. The non-lethal and yet serious health effects of MA use were not explored and, thus, even if the presence of MA reduces the population-level overdose mortality rate, the rise of other adverse health effects may counteract any public health benefits of fewer deaths.</p></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"11 ","pages":"Article 100238"},"PeriodicalIF":0.0,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772724624000222/pdfft?md5=3afdcc1751e39f904890e6b45823a55c&pid=1-s2.0-S2772724624000222-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140879661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and predictors of medication for opioid use disorder among reproductive-aged women","authors":"Jennifer K. Bello ,&nbsp;Nathaniel A. Dell ,&nbsp;Aaron M. Laxton ,&nbsp;Mary Conte ,&nbsp;Lynn Chen","doi":"10.1016/j.dadr.2024.100239","DOIUrl":"https://doi.org/10.1016/j.dadr.2024.100239","url":null,"abstract":"<div><h3>Background</h3><p>Women of reproductive age would benefit from treatment of opioid use disorder (OUD) prior to pregnancy to improve maternal and infant outcomes. In this study, we aimed to identify the prevalence of medication for OUD (MOUD) and characterize correlates of MOUD receipt among 12–49-year-old women with OUD seeking treatment in publicly funded substance use disorder treatment programs at the time of their first treatment episode.</p></div><div><h3>Methods</h3><p>This cross-sectional study explores the demographic and clinical characteristics of women of reproductive age with OUD receiving publicly funded substance use treatment services. We used data from the concatenated 2015–2021 Treatment Episode Data Set–Admissions (TEDS-A), which documents demographic and clinical characteristics of patient admissions to publicly funded substance use treatment services in the United States.</p></div><div><h3>Results</h3><p>In the sample of females aged 12–49 with no prior treatment admissions and primary OUD (n=325,512), 40.53% received MOUD (n=131,930), including 39.40% of non-pregnant women (n=115,315) and 52.79% of pregnant women (n=8423). Pregnant women had significantly higher odds of receiving MOUD (aOR = 2.42, 95%CI: 2.30, 2.54) compared to non-pregnant women. Non-white race, treatment setting, and treatment self-referral were also associated with higher levels of MOUD.</p></div><div><h3>Conclusions</h3><p>We identified a significant unmet need among both pregnant and non-pregnant women with OUD seeking care in publicly funded treatment clinics. While women who are pregnant are significantly more likely to receive evidence-based treatment with MOUD, still 47.21% of pregnant women did not receive MOUD. All reproductive-aged women with OUD should be offered evidence-based treatment options, including MOUD.</p></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"11 ","pages":"Article 100239"},"PeriodicalIF":0.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772724624000234/pdfft?md5=3275a5d80ed0d4a23aaede090ae920c2&pid=1-s2.0-S2772724624000234-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140813167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of a pilot brief educational intervention on preferences regarding treatments for opioid use disorder","authors":"Emaun Irani ,&nbsp;Colin Macleod ,&nbsp;Stephanie Slat ,&nbsp;Adrianne Kehne ,&nbsp;Erin Madden ,&nbsp;Kaitlyn Jaffe ,&nbsp;Amy Bohnert ,&nbsp;Pooja Lagisetty","doi":"10.1016/j.dadr.2024.100235","DOIUrl":"10.1016/j.dadr.2024.100235","url":null,"abstract":"<div><h3>Purpose</h3><p>Negative perceptions around medications for opioid use disorder (MOUD) amongst the public could deter patients with opioid use disorder (OUD) from engaging with MOUD. Thus, we evaluated whether a brief intervention could improve preferences for MOUD in people who may or may not use opioids.</p></div><div><h3>Methods</h3><p>We employed a pre-post design to assess the effect of a brief educational intervention on preferences for methadone, buprenorphine, naltrexone, and non-medication treatment in an online sample of US adults stratified by race, who may or may not use opioids. Respondents ranked their preferences in OUD treatment before and after watching four one-minute educational videos about treatment options. Changes in treatment preferences were analyzed using Bhapkar’s test and post hoc McNemar’s tests. A binary logistic generalized estimating equation (GEE) assessed factors associated with preference between treatments.</p></div><div><h3>Results</h3><p>The sample had 530 responses. 194 identified as White, 173 Black, 163 Latinx. Treatment preferences changed significantly towards MOUD (p&lt;.001). This effect was driven by changes toward buprenorphine (OR=2.38; p&lt;.001) and away from non-medication treatment (OR=0.20; p&lt;.001). There was no significant difference in effect by race/ethnicity. People with lower opioid familiarity were significantly more likely to change their preferences towards MOUD following the intervention.</p></div><div><h3>Conclusion</h3><p>Respondent preferences for MOUD increased following the intervention suggesting that brief educational interventions can change treatment preferences towards MOUD. These findings offer insights into perceptions of OUD treatment in a racially stratified sample and serve as a foundation for future educational materials that target MOUD preferences in the general public.</p></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"11 ","pages":"Article 100235"},"PeriodicalIF":0.0,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772724624000192/pdfft?md5=c08c9aef1f07d28dfdab5610fdc4b567&pid=1-s2.0-S2772724624000192-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140788870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabis use among adolescents and young adults during the COVID-19 pandemic: A systematic review","authors":"Yuni Tang ,&nbsp;Brenna Kirk ,&nbsp;Folawiyo Olanrewaju ,&nbsp;Christiaan G. Abildso ,&nbsp;Erin L. Winstanley ,&nbsp;Christa L. Lilly ,&nbsp;Toni M. Rudisill","doi":"10.1016/j.dadr.2024.100232","DOIUrl":"https://doi.org/10.1016/j.dadr.2024.100232","url":null,"abstract":"<div><h3>Background</h3><p>A systematic review of the literature was performed to summarize cannabis use among adolescents and young adults during the COVID-19 pandemic. Special focus was given to the prevalence of cannabis use during COVID-19, as well as factors that may explain changes in cannabis consumption patterns.</p></div><div><h3>Methods</h3><p>The protocol of this systematic review was registered. Articles from seven publication databases were searched in January 2022. The inclusion criteria for studies were as follows: 1) published in English; 2) study instruments needed to include items on COVID-19; 3) conducted after January 1st, 2020; 4) published in a peer-reviewed journal, dissertation, or thesis; 5) study population ≤25 years of age; 6) study designs were limited to observational analytical studies; 7) measured cannabis use. This review excluded other reviews, editorials, and conference abstracts that were not available as full text manuscripts. Independent review, risk of bias assessment, and data abstraction were performed by two authors.</p></div><div><h3>Results</h3><p>Fifteen articles from the United States (n=11) and Canada (n=4) were included in this review. The findings of this review showed that the prevalence of cannabis use during the pandemic among adolescents and young adults were mixed. Some mental health symptoms, including depression and anxiety, were identified as the most commonly reported reasons for increased cannabis use during the pandemic.</p></div><div><h3>Conclusions</h3><p>This review highlights the inconsistencies in the prevalence of cannabis use among adolescents and young adults during the pandemic. Therapeutic interventions for mental health and continued public health surveillance should be conducted to understand the long-term effects of cannabis use among adolescents and young adults.</p></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"11 ","pages":"Article 100232"},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772724624000167/pdfft?md5=95d1e28fc261d5e71432a3d71d967953&pid=1-s2.0-S2772724624000167-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140631650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The interacting effects of depression symptoms and sweet flavoring on the rewarding and reinforcing value of cigarillo use among young adults","authors":"Janet Audrain-McGovern ,&nbsp;Olivia Klapec ,&nbsp;Fodie Koita ,&nbsp;Divya Manikandan ,&nbsp;Matthew D. Stone","doi":"10.1016/j.dadr.2024.100234","DOIUrl":"https://doi.org/10.1016/j.dadr.2024.100234","url":null,"abstract":"<div><h3>Background</h3><p>Young adults 18–24 years old have the highest prevalence of cigarillo use, exposing young adults to comparable or higher nicotine levels and many of the same toxicants as combustible cigarettes. Identifying individual and product characteristics that increase the potential for persistent use is warranted. We sought to examine the interacting effects of depression symptoms and sweet flavoring on the rewarding and reinforcing value of cigarillo use.</p></div><div><h3>Methods</h3><p>86 young adults (18–24 years old, 73.3 % male, 38.4 % White, 33.7 % Black, and 27.9 % Other) completed three laboratory visits assessing the subjective rewarding value (exposure paradigm), relative reinforcing value (computerized choice task), and absolute reinforcing value (ad libitum cigarillo smoking session) of sweet-flavored versus non-flavored cigarillos. Depression symptoms were measured with the 20-item Center for Epidemiologic Studies of Depression Scale and treated as a continuous variable.</p></div><div><h3>Results</h3><p>General linear models with the appropriate family link tested differences in depressive symptomology for each outcome. Irrespective of flavor, greater cigarillo subjective reward was reported across increasing depressive symptomology (B=.0.03 [95%CI=0.00, 0.05], <em>p</em>=.017). Across symptom levels, no significant differences were observed in the subjective reward and relative and absolute reinforcing values of sweet-flavored versus non-flavored cigarillos (<em>p</em>’s &gt;.05).</p></div><div><h3>Conclusions</h3><p>Young adults with elevated depression find cigarillos more rewarding but not more reinforcing. They are not more vulnerable than young adults with lower symptom levels to sweet cigarillo flavoring. Public health prevention campaigns and tobacco product regulations aimed at preventing the initiation and escalation of young adult cigarillo use may impact young adults broadly.</p></div>","PeriodicalId":72841,"journal":{"name":"Drug and alcohol dependence reports","volume":"11 ","pages":"Article 100234"},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772724624000180/pdfft?md5=5207e3aa3b17dcdb007b01442cd417d6&pid=1-s2.0-S2772724624000180-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140558441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}